ENXTPA:IVABiotechs
Inventiva (ENXTPA:IVA) Is Up 25.0% After Fresh Analyst Support And Phase 3 Funding Boost
Leerink Partners recently initiated coverage on Inventiva with an Outperform rating and a US$12.00 price target, following earlier positive views from UBS and Wolfe Research on the company’s lead NASH/MASH candidate lanifibranor.
At the same time, Inventiva secured about US$172.5 million in planned equity financing alongside a US$150 million ADS offering, reinforcing funding for the fully enrolled Phase 3 NATiV3 trial in a disease area that still has no approved therapies.
We’ll now examine...